Daniel Lee Flynn - 15 Feb 2023 Form 4 Insider Report for Deciphera Pharmaceuticals, Inc. (DCPH)

Role
Chief Scientific Officer
Signature
/s/ Jeffrey M. Held, Attorney-in-Fact
Issuer symbol
DCPH
Transactions as of
15 Feb 2023
Net transactions value
-$20,686
Form type
4
Filing time
17 Feb 2023, 15:04:58 UTC
Previous filing
19 Jan 2023
Next filing
21 Jun 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DCPH Common Stock Award $0 +16,488 +38% $0.000000 60,183 15 Feb 2023 Direct F1
transaction DCPH Common Stock Sale $20,686 -1,370 -2.3% $15.10 58,813 16 Feb 2023 Direct F2
holding DCPH Common Stock 230,435 15 Feb 2023 By Daniel L. Flynn Revocable Trust
holding DCPH Common Stock 91,020 15 Feb 2023 By Daniel L. Flynn Irrevocable Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DCPH Stock Option (Right to Buy) Award $0 +65,900 $0.000000 65,900 15 Feb 2023 Common Stock 65,900 $15.48 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reporting person was awarded 16,488 Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest in three equal installments on each of February 15, 2024, February 15, 2025 and February 15, 2026.
F2 This sale was to cover tax liabilities in the vesting of restricted stock.
F3 This stock option was issued pursuant to the Issuer's 2017 Stock Option and Incentive Plan. The option shall vest in equal monthly installments over four years, beginning on March 15, 2023.